Genetic Causes, Diagnostics, and Testing
Rhabdomyolysis represents a potentially life-threatening syndrome characterized by skeletal muscle breakdown with release of intracellular contents into systemic circulation. The condition manifests through a spectrum of severity, from asymptomatic elevation of creatine kinase (CK) to life-threatening complications including acute kidney injury, electrolyte imbalances, and disseminated intravascular coagulation.
The diagnostic hallmark includes CK elevation exceeding five times the upper limit of normal, accompanied by clinical symptoms such as muscle pain, weakness, and dark urine indicating myoglobinuria. Understanding the underlying etiology proves crucial for appropriate management and prevention of recurrent episodes, particularly in genetic forms where specific interventions can dramatically improve outcomes.
Direct muscle injury represents the most straightforward mechanism of rhabdomyolysis. Crush injuries from accidents, natural disasters, or prolonged compression disrupt muscle cell membranes directly. Military personnel and athletes face risk from extreme exertion, particularly when combined with heat stress and dehydration. The pathophysiology involves mechanical disruption of sarcolemmal integrity, leading to calcium influx and activation of proteolytic enzymes.
Non-traumatic compression occurs in various clinical scenarios. Prolonged surgical procedures, particularly in lithotomy or lateral positions, can compromise muscle perfusion. Compartment syndrome develops when tissue pressure exceeds perfusion pressure, creating a vicious cycle of ischemia and edema.
Electrolyte abnormalities profoundly affect muscle membrane stability and energy metabolism. Severe hypokalemia, typically below 2.5 mEq/L, impairs muscle blood flow through arteriolar dysfunction. The mechanism involves Na-K-ATPase dysfunction, leading to intracellular sodium accumulation and subsequent cell swelling.
Hypophosphatemia depletes cellular ATP stores essential for maintaining membrane pumps. When phosphate levels fall below 1.0 mg/dL, muscles cannot maintain normal energy metabolism, particularly during increased demands. This explains why refeeding syndrome patients face high rhabdomyolysis risk.
Endocrine disorders create metabolic environments predisposing to muscle breakdown. Hypothyroidism impairs mitochondrial function and glycogenolysis, while thyrotoxicosis increases metabolic demands beyond muscle capacity. Diabetic emergencies combine multiple insults including hyperosmolarity, acidosis, and electrolyte shifts.
Medications cause rhabdomyolysis through various mechanisms. Statins, the most commonly implicated drugs, may deplete coenzyme Q10, disrupt prenylation of proteins, or cause immune-mediated myopathy. Risk increases with higher doses, drug interactions affecting metabolism, and genetic predisposition.
Recreational drugs pose significant risks through multiple mechanisms. Cocaine and amphetamines cause severe vasoconstriction, compromising muscle perfusion. Heroin users face additional risk from prolonged immobilization in awkward positions. Alcohol contributes through direct myotoxicity, electrolyte disturbances, and immobilization during intoxication.
McArdle disease exemplifies how genetic defects in energy metabolism cause exercise-induced rhabdomyolysis. The absence of muscle phosphorylase prevents glycogen breakdown, forcing muscles to rely solely on blood glucose and fatty acids.
Patients experience a characteristic "second wind" phenomenon where symptoms improve after 10–15 minutes as alternative fuel sources become available. The p.R50X mutation accounts for 40–50% of alleles in Caucasian populations, causing complete enzyme deficiency.
Tarui disease involves phosphofructokinase deficiency, blocking glycolysis at a crucial regulatory step. Unlike McArdle disease, patients cannot utilize glucose effectively even when available. The additional feature of hemolytic anemia results from the same enzyme defect in red blood cells, providing a diagnostic clue.
Pompe disease presents differently across age groups. Late-onset forms may present primarily with exercise intolerance and rhabdomyolysis before respiratory muscle weakness becomes apparent. The pathophysiology involves both lysosomal glycogen accumulation and secondary mitochondrial dysfunction.
Carnitine palmitoyltransferase II (CPT II) deficiency represents the most common cause of recurrent exertional rhabdomyolysis in adults. The enzyme catalyzes a rate-limiting step in long-chain fatty acid oxidation, particularly important during prolonged exercise when glycogen stores deplete. The p.S113L mutation, found in 60% of disease alleles, produces a temperature-sensitive enzyme explaining why cold exposure triggers episodes.
Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency affects the initial step of mitochondrial fatty acid beta-oxidation. The clinical spectrum ranges from severe neonatal cardiomyopathy to mild adult-onset myopathy. Residual enzyme activity correlates with phenotype severity, with adult-onset cases typically maintaining 10–30% activity.
MADD disrupts multiple steps in fatty acid oxidation through defects in electron transfer flavoproteins. The severe lipid accumulation distinguishes this from single enzyme defects, often causing a characteristic "lipid storage myopathy" appearance on muscle biopsy.
Primary mitochondrial myopathies result from mutations affecting the respiratory chain, either in mitochondrial DNA or nuclear genes encoding mitochondrial proteins. The hallmark "ragged red fibers" represent subsarcolemmal mitochondrial proliferation, a compensatory response to defective oxidative phosphorylation.
Coenzyme Q10 deficiency deserves special attention as a treatable cause of mitochondrial dysfunction. Primary deficiency results from mutations in COQ genes involved in ubiquinone biosynthesis. Secondary deficiency may occur in other mitochondrial disorders or with statin use. Early supplementation can prevent irreversible muscle damage.
Dystrophinopathies illustrate how structural protein defects cause rhabdomyolysis. In Duchenne muscular dystrophy, complete dystrophin absence causes severe sarcolemmal instability. Becker muscular dystrophy, with partial dystrophin function, may present initially with exertional rhabdomyolysis before weakness develops.
Limb-girdle muscular dystrophies (LGMDs) frequently present with rhabdomyolysis as the initial symptom. Dysferlinopathy (LGMD R2) particularly mimics inflammatory myopathy with CK elevations exceeding 10,000 IU/L and inflammatory infiltrates on biopsy. The protein normally functions in membrane repair, explaining exercise-induced damage.
Malignant hyperthermia susceptibility involves mutations in calcium release channels (RYR1) or voltage sensors (CACNA1S). Beyond anesthetic triggers, some mutations cause exertional rhabdomyolysis without drug exposure. The pathophysiology involves uncontrolled sarcoplasmic reticulum calcium release overwhelming cellular buffering capacity.
RYR1-related myopathies span a clinical spectrum from severe neonatal presentations to mild adult-onset forms. The location and nature of mutations influence phenotype, with central core disease representing one manifestation of RYR1 dysfunction.
Proper muscle biopsy technique critically affects diagnostic yield. Open surgical biopsy remains preferred over needle biopsy, providing adequate tissue for multiple analyses. The biopsy site should target clinically affected but not end-stage muscle, as severe fibrosis and fatty replacement obscure diagnostic features.
Immediate specimen processing prevents artifacts. Fresh tissue must be divided for different preparations: flash-freezing in isopentane cooled by liquid nitrogen preserves enzyme activity for histochemistry, glutaraldehyde fixation enables electron microscopy, and a portion should be saved for biochemical analysis. Improper freezing causes ice crystal artifacts that can mimic pathology.
The basic histochemical panel provides crucial diagnostic information:
Specific enzyme stains target suspected defects. Myophosphorylase staining diagnoses McArdle disease definitively, showing absent activity except in smooth muscle vessels serving as internal controls. Phosphofructokinase staining similarly identifies Tarui disease. These simple stains can provide immediate diagnosis, avoiding the need for genetic testing.
Dystrophin analysis using antibodies against different domains distinguishes Duchenne (absent) from Becker (reduced/patchy) muscular dystrophy. The sarcoglycan complex (alpha, beta, gamma, delta) identifies specific LGMD subtypes, though secondary reductions complicate interpretation. Dysferlin absence confirms LGMD2B, while preserved staining excludes this diagnosis.
Ultrastructural analysis reveals pathology invisible by light microscopy. Glycogen storage diseases show characteristic accumulation patterns: subsarcolemmal pools in McArdle disease versus membrane-bound lysosomal storage in Pompe disease. Paracrystalline inclusions indicate mitochondrial proliferation in response to dysfunction. Lipid droplet accumulation patterns distinguish various fatty acid oxidation defects.
When clinical presentation strongly suggests a specific disorder, targeted testing offers the most efficient diagnosis. CPT II deficiency presenting with classic triggers warrants initial p.S113L mutation analysis, detecting 60% of cases. If negative, full gene sequencing follows. This stepwise approach balances cost and diagnostic yield.
Founder mutations in specific populations guide targeted testing. The c.191dupA mutation in ANO5 accounts for 70% of Northern European anoctaminopathy cases. Similarly, specific DYSF mutations predominate in Libyan Jewish and Japanese populations.
Next-generation sequencing enables simultaneous analysis of multiple genes. Rhabdomyolysis panels typically include 30–50 genes covering metabolic myopathies, muscular dystrophies, and mitochondrial disorders. Panel composition varies between laboratories, requiring careful selection based on clinical suspicion.
Panels cannot detect deep intronic mutations, may miss copy number variants in some genes, and frequently identify variants of uncertain significance requiring interpretation. Panels also cannot detect mitochondrial DNA mutations without specific inclusion.
Exome sequencing examines protein-coding regions where most disease-causing mutations occur. This approach succeeds particularly for rare disorders not included in standard panels or novel gene discoveries. The diagnostic yield in undiagnosed myopathies approaches 25–40%.
Variants of uncertain significance often require functional studies. Enzyme assays in patient cells or tissues directly demonstrate deficiency. Expression studies in cell culture systems can assess protein stability and localization. Specialized tests like in vitro contracture testing for malignant hyperthermia provide functional confirmation.
The PYGM gene spans 20 exons encoding muscle glycogen phosphorylase. Over 150 mutations are reported, with p.R50X (nonsense) most prevalent in Caucasians and p.G205S (missense) in Spanish populations. Most mutations cause complete enzyme absence, though rare missense variants retain minimal activity associated with milder phenotypes. Genetic testing achieves >95% sensitivity when combining sequencing and deletion analysis.
Phosphofructokinase muscle subunit mutations show ethnic clustering. Japanese patients commonly carry splicing mutations while Ashkenazi Jewish populations have distinct missense variants. The enzyme exists as homotetramers in muscle and heterotetramers in red cells, explaining tissue-specific manifestations.
| Type | Deficiency | Gene(s) |
|---|---|---|
| GSD III | Debrancher deficiency | AGL |
| GSD IV | Brancher deficiency | GBE1 |
| GSD IX | Phosphorylase kinase deficiency | PHKA1, PHKB, PHKG2, CALM1 |
| GSD X | Phosphoglycerate mutase deficiency | PGAM2 |
| GSD XI | Lactate dehydrogenase deficiency | LDHA |
| GSD XII | Aldolase deficiency | ALDOA |
| GSD XIII | β-enolase deficiency | ENO3 |
Three clinical phenotypes correlate with mutation severity. The lethal neonatal form results from severe mutations like large deletions. Infantile hepatocardiomuscular presentation involves mutations reducing activity below 10%. The adult myopathic form typically involves the thermolabile p.S113L variant, explaining cold-induced episodes.
The ACADVL gene encodes a homodimeric enzyme specific for C14–C20 fatty acids. Null mutations cause severe neonatal presentation while missense mutations like p.V283A retain partial activity permitting survival to adulthood. Temperature-sensitive variants explain fever-triggered decompensations.
| Deficiency | Gene | Key Features |
|---|---|---|
| SCAD | ACADS | Often asymptomatic variant |
| MCAD | ACADM | Common p.A985G mutation |
| ETF | ETFA, ETFB | Multiple acyl-CoA dehydrogenase deficiency |
| ETF-QO | ETFDH | Riboflavin-responsive forms exist |
| LCHAD | HADHA | Maternal AFLP association |
| TFP | HADHA, HADHB | Both subunits required |
| SCHAD | HADH | Hyperinsulinism association |
| Carnitine transporter | SLC22A5 | Primary carnitine deficiency |
| CPT I | CPT1A | Hepatic presentation, no myopathy |
| CACT | SLC25A20 | Severe neonatal form |
| Complex | Genes |
|---|---|
| Complex I | NDUFS1, NDUFV1, NDUFA1, and >40 others |
| Complex II | SDHA, SDHB, SDHC, SDHD, SDHAF1 |
| Complex III | UQCRB, UQCRQ, UQCRC2, CYC1, UQCC2 |
| Complex IV | SURF1, SCO2, COX10, COX15, COA3–8 |
| Complex V | ATP5A1, ATP5E, ATPAF2 |
| CoQ10 biosynthesis | COQ2, COQ4, COQ6, COQ7, COQ8A, COQ8B, COQ9 |
| mtDNA maintenance | POLG, POLG2, C10orf2 (Twinkle), TK2, DGUOK, RRM2B, SUCLA2, SUCLG1, AGK, MPV17, SPG7, TYMP, SLC25A4 |
The enormous DMD gene (79 exons, 2.4 Mb) explains the high mutation rate. Deletions cluster in hotspots (exons 45–53 and 2–10), detectable by MLPA. Reading frame rule predicts phenotype: frame-disrupting mutations cause Duchenne while in-frame changes cause Becker. Female carriers occasionally manifest through skewed X-inactivation.
| Subtype | Gene | Key Features |
|---|---|---|
| LGMD R3 (α-sarcoglycan) | SGCA | Severe childhood onset |
| LGMD R4 (β-sarcoglycan) | SGCB | Similar to Duchenne |
| LGMD R5 (γ-sarcoglycan) | SGCG | Variable severity |
| LGMD R6 (δ-sarcoglycan) | SGCD | Cardiomyopathy prominent |
| LGMD R1 (Calpain-3) | CAPN3 | Eosinophilic infiltrates |
| LGMD R2 (Dysferlin) | DYSF | Very high CK, inflammation |
| LGMD R9 (FKRP) | FKRP | c.826C>A common mutation |
| LGMD R12 (Anoctamin-5) | ANO5 | Male predominance |
| LGMD D4 (Caveolin-3) | CAV3 | Rippling muscle phenomenon |
The massive RYR1 gene (106 exons) encodes the skeletal muscle calcium release channel. Over 700 variants are reported with three hotspots for dominant malignant hyperthermia mutations. Recessive mutations throughout the gene cause various congenital myopathies.
| Disorder | Gene | Mechanism |
|---|---|---|
| Hyperkalemic PP | SCN4A | Affected fast inactivation |
| Hypokalemic PP Type 1 | CACNA1S | Voltage sensor mutation |
| Hypokalemic PP Type 2 | SCN4A | Gating pore creation |
| Andersen-Tawil syndrome | KCNJ2 | Inward rectifier affected |
| Myotonia congenita | CLCN1 | Chloride channel mutations |
| Paramyotonia congenita | SCN4A | Cold sensitivity mutations |
Mild exertional familial rhabdomyolysis represents a distinct clinical entity characterized by recurrent episodes triggered by prolonged physical activity, typically exceeding 30–45 minutes duration. These patients maintain normal strength between episodes and often participate in regular activities without difficulty.
The typical presentation involves young adults experiencing muscle pain, weakness, and dark urine following unaccustomed or prolonged exercise. Unlike severe metabolic defects presenting in childhood, these milder forms may remain undiagnosed until military training, athletic participation, or unusual physical demands unmask the underlying defect. Recognition of this pattern should prompt systematic genetic evaluation rather than attributing symptoms to deconditioning alone.
The adult myopathic form typically manifests in the second or third decade with exercise-induced symptoms. The p.S113L mutation produces a thermolabile enzyme explaining why cold exposure compounds exercise risk.
Management focuses on preventive strategies: avoiding prolonged fasting before exercise, carbohydrate loading before extended activity, medium-chain triglyceride supplementation to bypass the enzymatic defect, and maintaining glucose intake during illness to prevent metabolic decompensation.
Several muscular dystrophies manifest initially with exercise-induced rhabdomyolysis before weakness becomes apparent:
The evaluation begins with detailed history emphasizing triggers, duration of exercise tolerance, associated factors (fasting, heat, illness), and family history.
| Trigger Pattern | Priority Testing |
|---|---|
| Prolonged exercise + fasting | CPT2 gene (p.S113L first), then full FAO defect panel |
| Shorter exercise triggers | PYGM (McArdle) first, then other glycogenoses |
| Elevated baseline CK between episodes | Muscular dystrophy panel; consider biopsy with immunostaining |
| Heat + exercise triggers | RYR1 analysis; consider in vitro contracture testing |
General principles apply across diagnoses: education about triggers, hydration and electrolyte balance during exercise, gradual conditioning, and emergency protocols for acute episodes including aggressive hydration, alkalinization of urine, and monitoring for complications.
Specific dietary interventions target underlying defects: high-carbohydrate diets benefit glycogen storage diseases while medium-chain triglycerides help FAO defects. Some conditions respond to cofactor supplementation such as riboflavin for some ETF-QO mutations or CoQ10 for primary deficiency.
The prognosis for mild exertional rhabdomyolysis generally remains favorable. Most patients achieve good quality of life with appropriate precautions. Genetic counseling addresses recurrence risks and enables cascade screening of at-risk relatives.
Age at onset provides initial stratification: neonatal/infantile presentation suggests severe metabolic defects while adult onset favors milder variants or structural myopathies. Exercise duration triggering symptoms distinguishes metabolic defects (prolonged exercise) from channelopathies (brief intense activity).
First-tier testing maximizes diagnostic yield while minimizing cost:
Second-tier testing follows negative initial screens: urine organic acids during acute episodes, lactate and pyruvate measurements, specific enzyme assays in lymphocytes or fibroblasts, and dried blood spot testing for carnitine and acylcarnitine analysis.
Clear indications include negative genetic testing despite strong clinical suspicion, atypical presentations requiring histopathologic clarification, and distinguishing acquired from genetic myopathies.
Avoid the immediate post-rhabdomyolysis period when necrosis obscures specific features. Select clinically affected but not end-stage muscle. Coordinate with the laboratory to ensure proper specimen handling for planned analyses.
| Diagnosis Group | Prevention Strategies |
|---|---|
| Glycogen storage diseases | Frequent carbohydrate intake; pre-exercise carbohydrate loading; corn starch before sleep; vitamin B6 supplementation (McArdle) |
| FAO defects | Avoid fasting >10–12h in adults; maintain glucose during illness; MCT supplementation; bezafibrate (investigational) |
| Mitochondrial disorders | Interval training; CoQ10 supplementation for primary deficiency; avoid exercise during illness |
Most metabolic myopathies follow autosomal recessive inheritance with 25% recurrence risk. Cascade screening identifies presymptomatic relatives who benefit from preventive measures. This proves particularly valuable for treatable conditions like CPT II deficiency. Address insurance and employment discrimination concerns. Discuss anesthesia risk implications in RYR1 mutations requiring family notification.
Gene therapy trials target various muscular dystrophies and metabolic myopathies. Enzyme replacement therapy, successful in Pompe disease, extends to other conditions. Small molecule therapies include read-through agents for nonsense mutations and pharmacological chaperones stabilizing misfolded proteins. Connect patients with disease-specific registries and research networks.
This comprehensive guide synthesizes current knowledge in neuromuscular genetics, metabolic myopathies, and diagnostic approaches to rhabdomyolysis. For specific clinical decisions, consultation with neuromuscular specialists and reference to current clinical guidelines is recommended. Genetic testing capabilities and interpretations continue to evolve rapidly, necessitating regular updates to diagnostic algorithms.